Reactions to recent data on the integration of CD19-targeted therapies into the treatment of patients with diffuse large B-cell lymphoma.
EP. 8: Individualized Therapy for Unfit Patients With R/R DLBCL
November 12th 2021Implications for treating unfit patients with relapsed/refractory diffuse large B-cell lymphoma with chemotherapy or the combination of tafasitamab and lenalidomide based on patient characteristics and the L-MIND trial.
Watch
EP. 9: Frontline Therapy for R/R DLBCL: TAFA/LEN/R-CHOP
November 24th 2021Drs John M. Burke and Marin F. Xavier consider the potential utilization of tafasitamab plus lenalidomide plus R-CHOP chemotherapy vs R-CHOP chemotherapy alone as relapsed/refractory diffuse large B-cell lymphoma treatment.
Watch